company background image
BLRX logo

BioLineRx TASE:BLRX Stock Report

Last Price

₪0.025

Market Cap

₪55.8m

7D

-34.2%

1Y

-91.6%

Updated

01 Feb, 2025

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

BioLineRx Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BioLineRx
Historical stock prices
Current Share Price₪0.025
52 Week High₪0.35
52 Week Low₪0.024
Beta1.02
1 Month Change-63.77%
3 Month Change-78.81%
1 Year Change-91.61%
3 Year Change-93.47%
5 Year Change-94.97%
Change since IPO-99.96%

Recent News & Updates

Recent updates

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

Apr 02
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Aug 25
BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Apr 05
Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Is BioLineRx (TLV:BLRX) A Risky Investment?

Jun 17
Is BioLineRx (TLV:BLRX) A Risky Investment?

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Feb 26
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Oct 17
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Shareholder Returns

BLRXIL BiotechsIL Market
7D-34.2%-5.1%-0.6%
1Y-91.6%-20.8%31.9%

Return vs Industry: BLRX underperformed the IL Biotechs industry which returned -24.5% over the past year.

Return vs Market: BLRX underperformed the IL Market which returned 31.8% over the past year.

Price Volatility

Is BLRX's price volatile compared to industry and market?
BLRX volatility
BLRX Average Weekly Movement17.7%
Biotechs Industry Average Movement9.4%
Market Average Movement4.5%
10% most volatile stocks in IL Market9.2%
10% least volatile stocks in IL Market3.0%

Stable Share Price: BLRX's share price has been volatile over the past 3 months compared to the IL market.

Volatility Over Time: BLRX's weekly volatility has increased from 12% to 18% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200379Phil Serlinwww.biolinerx.com

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.

BioLineRx Ltd. Fundamentals Summary

How do BioLineRx's earnings and revenue compare to its market cap?
BLRX fundamental statistics
Market cap₪55.82m
Earnings (TTM)-₪71.26m
Revenue (TTM)₪78.67m

0.7x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLRX income statement (TTM)
RevenueUS$21.99m
Cost of RevenueUS$6.87m
Gross ProfitUS$15.13m
Other ExpensesUS$35.04m
Earnings-US$19.92m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0089
Gross Margin68.78%
Net Profit Margin-90.57%
Debt/Equity Ratio326.9%

How did BLRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 11:35
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioLineRx Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Michael KingJMP Securities
Justin WalshJonesTrading Institutional Services, LLC